FDA Approves Spiriva An inhaled treatment that can help victims of chronic obstructive pulmonary disease (COPD) has been approved by the Food and Drug Administration. Spiriva HandiHaler is expected to be on sale by midsummer, according to the maker, Boehringer Ingelheim Pharmaceuticals, Inc. Spiriva is designed for one-a-day use to help open narrowed bronchial pathways, easing breathing in patients suffering from COPD, which includes chronic bronchitis and emphysema. Spiriva, already available in other countries, will be co-marketed in the United States by Pfizer, Inc. For more information go to FDA Approves Spiriva For more information, contact Lynn Carol at the Association.

Home  About us  Experience the Wow  Sponsorships  Donations  Volunteer  Press Releases  Advocacy  Info For Kids  Info for Adults  Info For Practitioners  Calendar  Links  Article Archives

The mission of the American Lung Association is to prevent lung disease and promote lung health.